Xu Wenjing, Ye Chunping, Qing Xin, Liu Shengli, Lv Xinyi, Wang Wenjun, Dong Xiaochen, Zhang Yewei
School of Medicine, Southeast University, Nanjing, 210009, China.
Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care Hospital, Women's Hospital of Nanjing Medical University, Nanjing, China.
Mater Today Bio. 2022 Jul 12;16:100358. doi: 10.1016/j.mtbio.2022.100358. eCollection 2022 Dec.
Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking the activity of tyrosine kinase. However, the toxicity and drug resistance of MTKIs severely restrict their further clinical application. The nano pharmaceutical technology based on MTKIs has attracted ever-increasing attention in recent years. Researchers deliver MTKIs through various types of nanocarriers to overcome drug resistance and improve considerably therapeutic efficiency. This review intends to summarize comprehensive applications of MTKIs nanoparticles in malignant tumor treatment. Firstly, the mechanism and toxicity were introduced. Secondly, various nanocarriers for MTKIs delivery were outlined. Thirdly, the combination treatment schemes and drug resistance reversal strategies were emphasized to improve the outcomes of cancer therapy. Finally, conclusions and perspectives were summarized to guide future research.
多靶点酪氨酸激酶抑制剂（MTKIs）在肿瘤治疗中已引起广泛关注。MTKIs可通过阻断酪氨酸激酶的活性来抑制肿瘤细胞增殖并诱导细胞凋亡。然而，MTKIs的毒性和耐药性严重限制了它们的进一步临床应用。近年来，基于MTKIs的纳米药物技术越来越受到关注。研究人员通过各种类型的纳米载体递送MTKIs，以克服耐药性并显著提高治疗效果。本综述旨在总结MTKIs纳米颗粒在恶性肿瘤治疗中的综合应用。首先，介绍了其作用机制和毒性。其次，概述了用于递送MTKIs的各种纳米载体。第三，强调了联合治疗方案和耐药性逆转策略，以改善癌症治疗的效果。最后，总结了结论和展望，以指导未来的研究。
Zotero 插件
